These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1097096)

  • 1. Phase I. evaluation of cyclocytidine (NSC-145668).
    Lokich JJ; Chawla PL; Jaffe N; Frei E
    Cancer Chemother Rep; 1975; 59(2 Pt 1):389-93. PubMed ID: 1097096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letter: Myelotoxicity and orthostatic hypotension of cyclocytidine (NSC-145668).
    Minow RA; Gottlieb JA; O'Bryan RM; Hoogstraten B
    Cancer Treat Rep; 1976 Mar; 60(3):215-6. PubMed ID: 1260775
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878) in mice.
    Liss RH; Neil GL
    Cancer Chemother Rep; 1975; 59(3):501-13. PubMed ID: 1203880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II evaluation of cyclocytidine.
    Burgess MA; Bodey GP; Minow RA; Gottlieb JA
    Cancer Treat Rep; 1977; 61(3):437-43. PubMed ID: 68828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors.
    Finklestein JZ; Higgins G; Krivit W; Hammond D
    Cancer Treat Rep; 1979 Aug; 63(8):1331-3. PubMed ID: 89907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies.
    Muss HB; Capizzi RL; Atkins JN; Powell BL; Cooper MR; Ferree D; McMahan RA; Jobson V; Craig J; Homesley HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):166-70. PubMed ID: 4040264
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors.
    Davis HL; Rochlin DB; Weiss AJ; Wilson WL; Andrews NC; Madden R; Sedransk N
    Oncology; 1974; 29(3):190-200. PubMed ID: 4412696
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect and toxicity of combination treatment including cyclocytidine or cytosine arabinoside in L-1210 and sarcoma-180 systems.
    Hoshi A; Kanzawa F; Iigo M; Kuretani K
    Gan; 1975 Oct; 66(5):539-46. PubMed ID: 1220992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclocytidine chemotherapy for malignant melanoma.
    McKelvey EM; Hewlett JS; Thigpen T; Whitecar J
    Cancer Treat Rep; 1978 Mar; 62(3):469-71. PubMed ID: 77191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
    Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
    Odujinrin OO; DeConti RC; Bertino JR
    Cancer Chemother Rep; 1975; 59(6):1091-6. PubMed ID: 769948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clincal pharmacology of O2,2'-cyclocytidine.
    Rodriguez DH; Loo TL; Bodey GP; Freireich EJ
    Clin Pharmacol Ther; 1975 Jan; 17(1):66-72. PubMed ID: 1173058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclocytidine in the treatment of refractory acute childhood leukemia: a Southwest Oncology Group Phase I-II study.
    Miale T; Hvizdala E; Ragab A; Pullen J; O'Brien P; McMillan C
    Cancer Treat Rep; 1979; 63(11-12):1913-5. PubMed ID: 93513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of piperazinedione in patients with advanced cancer.
    Currie V; Woodcock T; Tan C; Krakoff I; Young C
    Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the cardiovascular actions of cyclocytidine.
    Burks TF; Loo TL; Grubb MN
    Proc Soc Exp Biol Med; 1978 Dec; 159(3):374-9. PubMed ID: 83653
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
    Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of acute leukemia with 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride (cyclocytidine) (author's transl)].
    Masaoka T; Hasegawa Y; Tatsumi N; Nakamura H; Yoshitake J
    Rinsho Ketsueki; 1973 Aug; 14(8):877-81. PubMed ID: 4797128
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I trial and clinical pharmacology of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea.
    Woolley PV; Luc PV; Rahman A; Korsmeyer SJ; Smith FP; Schein PS
    Cancer Res; 1981 Oct; 41(10):3896-900. PubMed ID: 7284999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.